drugset / Trial / NCT02429843
A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer
Phase 1
Completed
16 enrolled
University of Alabama at Birmingham
Tracon Pharmaceuticals Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a single center, open-label, nonrandomized, phase 1b study of TRC105 in combination with standard dose treatment in patients with stage IV non-squamous non-small cell lung cancer.
Timeline
- Start
- 2015-11-02
- Primary completion
- 2018-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carotuximab | Monoclonal antibody | 6 mg/kg | Intravenous |
| Subject | Carotuximab | Monoclonal antibody | 8 mg/kg | Intravenous |
| Subject | Carotuximab | Monoclonal antibody | 10 mg/kg | Intravenous |